Why the study?
Atrial remodelling promotes AF, and BMP10 is an atrial-specific biomarker released during structural changes, motivating validation of whether BMP10 is associated with AF recurrence after catheter ablation.
Is baseline BMP10 plasma concentration associated with atrial fibrillation recurrence in patients undergoing first elective catheter ablation?
Is baseline BMP10 plasma concentration associated with atrial fibrillation recurrence in patients undergoing first elective catheter ablation?
Higher baseline plasma concentrations of the atrial-specific biomarker BMP10 are independently associated with an increased risk of atrial fibrillation recurrence after first elective catheter ablation.
Answers are grounded in this paper and cite their sources.
BMP10 may stratify post-ablation AF recurrence risk; hypothesis-generating and leaves clinical use open pending prospective trials.
AIMS: Atrial remodelling, defined as a change in atrial structure, promotes atrial fibrillation (AF). Bone morphogenetic protein 10 (BMP10) is an atrial-specific biomarker released to blood during atrial development and structural changes. We aimed to validate whether BMP10 is associated with AF recurrence after catheter ablation (CA) in a large cohort of patients. METHODS AND RESULTS: We measured baseline BMP10 plasma concentrations in AF patients who underwent a first elective CA in the prospective Swiss-AF-PVI cohort study. The primary outcome was AF recurrence lasting longer than 30 s during a follow-up of 12 months. We constructed multivariable Cox proportional hazard models to determine the association of BMP10 and AF recurrence. A total of 1112 patients with AF (age 61 ± 10 years, 74% male, 60% paroxysmal AF) was included in our analysis. During 12 months of follow-up, 374 patients (34%) experienced AF recurrence. The probability for AF recurrence increased with increasing BMP10 concentration. In an unadjusted Cox proportional hazard model, a per-unit increase in log-transformed BMP10 was associated with a hazard ratio (HR) of 2.28 (95% CI 1.43; 3.62, P < 0.001) for AF recurrence. After multivariable adjustment, the HR of BMP10 for AF recurrence was 1.98 (95% CI 1.14; 3.42, P = 0.01), and there was a linear trend across BMP10 quartiles (P = 0.02 for linear trend). CONCLUSION: The novel atrial-specific biomarker BMP10 was strongly associated with AF recurrence in patients undergoing CA for AF. CLINICALTRIALS.GOV IDENTIFIER: NCT03718364; https://clinicaltrials.gov/ct2/show/NCT03718364.
No takes yet. Share an insight, caveat, or question.
Hennings et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: